Cell therapy offers another option for addressing the most difficult blood cancer cases, but such treatments, which are engineered from a patient’s own immune cells, don’t yet work on solid tumors. Neogene Therapeutics is developing technology with the potential to bring cell therapies to solid tumors and it now has $110 million to advance its research toward human testing.
The experimental therapies of Amsterdam-based Neogene target neoantigens, which are, as the term suggests, new antigens. These proteins arise from the mutations that drive cancer and they’re abundant on the surface of cancer cells but absent on healthy cells. That distinction makes… Read more »
UNDERWRITERS AND PARTNERS
